# Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

> **NCT04976192** · PHASE3 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 608 (actual)

## Conditions studied

- Chronic Urticaria

## Interventions

- **COMBINATION_PRODUCT:** TEV-45779
- **COMBINATION_PRODUCT:** XOLAIR® Injection

## Key facts

- **NCT ID:** NCT04976192
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-30
- **Primary completion:** 2024-04-05
- **Final completion:** 2024-04-05
- **Target enrollment:** 608 (ACTUAL)
- **Last updated:** 2025-10-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04976192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04976192, "Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04976192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*